FNDC5 relates to skeletal muscle IGF-I and mitochondrial function and gene expression in obese men with reduced growth hormone.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

To investigate the relationship of skeletal muscle FNDC5 mRNA expression and circulating irisin to the GH/IGF-I axis and to skeletal muscle mitochondrial function and mitochondria-related gene expression in obese men.

Before and after treatment, they underwent (31)P-magnetic resonance spectroscopy to evaluate phosphocreatine (PCr) recovery as a measure of mitochondrial function and skeletal muscle biopsy to assess expression of mitochondrial-related genes.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, men only.

How the Study Was Run

Serum irisin and IGF-I and skeletal muscle FNDC5 and IGF-I mRNA were measured.

What Was Measured

Topics PubMed links to this paper include Fibronectins, Gene Expression, Human Growth Hormone, Hypopituitarism, Insulin-Like Growth Factor I, Mitochondria and Muscle, Skeletal.

The authors tagged it with the keywords FNDC5, IGF-I, Irisin, Mitochondrial, Obesity and Skeletal muscle.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.